Skip to main content
Landing Pages / Profile
Photo of  Thomas J. Herzog, MD

Thomas J. Herzog, MD

Adjunct Professor

Deputy Director, University of Cincinnati Cancer Center; Paul and Carolyn Flory

Obstetrics & Gynecology | College of Medicine

  • Fellowship: Washington University School of Medicine (Gynecologic Oncology)
  • Residency: Good Samaritan Hospital (Obstetrics and Gynecology)
  • Medical Degree: University of Cincinnati (Obstetrics and Gynecology Gynecologic Oncology)
  • Bachelor's Degree: Miami University (Zoology)
Board Certifications & Licenses

American Board of Obstetrics and Gynecology (Gynecologic Oncology) (Certification Date: 1997-04-09) - (Recertification Date: 2023-12-31)
American Board of Obstetrics and Gynecology (Certification Date: 1995-11-17) - (Recertification Date: 2023-12-31)


Gynecologic Oncology
Obstetrics and Gynecology

Contact Information

Clinical Interests

Gynecologic Oncology

Obstetrics and Gynecology



Adnexal Disease

Adnexal Tumors

Cervical Cancer


Embryonal Carcinoma

Embryonal Tumors

Endometrial Cancer

Endometrial Stromal Sarcoma


Fallopian Tube Cancer


Germ Cell and Embryona Cancers

Germ Cell Tumor

Gestational Trophoblastic Neoplasia

Human Papilloma Virus (HPV)

Krukenberg Tumor

Other Complicated Gynecologic Cancers

Ovarian Cancer

Ovarian Cyst

Pelvic Cancers

Pelvic Masses

Placenta Accreta

Precancer in the Vagina

Precancer in the Vulva

Precancers in the Cervix

Uterine Fibroids (Uterine leiomyoma)

Uterine Hemorrhage

Uterine Polyps (Endometrial Polyps)

Uterine Sarcoma

Vaginal Cancer

Vulvar Cancer

Peer Reviewed Publications

Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381

Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512

Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42

Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346

Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271

Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589

Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625

Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525

Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254